Defining a role for contrast-enhanced ultrasound in endovascular aneurysm repair surveillance  by Millen, Alistair et al.
From
D
H
Auth
Rep
V
H
do
The
to
m
0741
Cop
http
18Deﬁning a role for contrast-enhanced ultrasound in
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Richard G. McWilliams, EBIR, FRCR,b Steve Wallace, BSc (Hons), AVS,a
Srinivasa R. Vallabhaneni, MD, FRCS, EBSQ-Vasc,a and Robert K. Fisher, MD, FRCS,a Liverpool,
United Kingdom
Objective: Endovascular aneurysm repair (EVAR) surveillance includes duplex ultrasound, abdominal radiography, and
computed tomography angiography. Contrast-enhanced ultrasound (CEUS) has emerged as an additional modality
whose role remains undeﬁned. We evaluated whether a potential role for CEUS was the elucidation of unresolved issues
following standard surveillance modalities.
Methods: All patients undergoing EVAR at a tertiary referral center had surveillance based on plain abdominal radiograph
and duplex ultrasound, with single arterial phase computed tomography angiography reserved for abnormalities or
nondiagnostic imaging. In this prospective evaluation, from April 2010 to July 2011, discordance between imaging
modalities or unresolved surveillance issues prompted CEUS. Cases and imaging were discussed in a multidisciplinary
setting and outcomes recorded.
Results:During the study period, 539 patients underwent EVAR surveillance, of whom 33 (6%) had CEUS for unresolved
issues (median age, 79; range, 66-90; 28 male). Median follow-up after EVAR was 23 months (range, 0-132). In all cases,
CEUS was able to resolve the clinical issue, resulting in secondary intervention in 10 patients (30%). The remaining
patients were returned to surveillance.
Within the cohort of 33 patients, the clinical issues were categorized into three groups. Group 1: Endoleak of uncertain
classiﬁcation (n [ 27: 21 type II, four type I, two had endoleak excluded). Group 2: Signiﬁcant aneurysm expansion
($5 mm) without apparent endoleak (n[ 4: one type II, three had endoleak excluded). Group 3: Target vessel patency
following fenestrated EVAR (n [ 2: patency conﬁrmed in both).
Conclusions: CEUS can enhance EVAR surveillance through clariﬁcation of endoleak and target vessel patency when
standard imaging modalities are not diagnostic. (J Vasc Surg 2013;58:18-23.)Surveillance following endovascular aneurysm repair with the use of CTA reserved for special cases, has been
(EVAR) is intended to identify features that potentially
threaten stent graft durability.1,2 An endoleak represents
the most frequent complication after EVAR and has an
incidence ranging from 10% to 45%.3 Endoleaks are classi-
ﬁed according to their origin.4 Type I and III are graft-
related endoleaks, which require urgent intervention to
relieve aneurysm re-pressurization. By comparison, type
II endoleaks are usually observed as they are frequently
benign and may resolve spontaneously.4
Computed tomography angiography (CTA) remains
the most utilized modality of surveillance imaging.5 Multi-
phasic CTA has satisfactory speciﬁcity and sensitivity for
endoleak identiﬁcation,6-8 although it is less able to classify
them.9 Surveillance based on duplex ultrasound (DUS) in
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contrast-induced nephropathy, reduced ionizing radiation
exposure, and cost.10 AXR performed according to the
Liverpool-Perth protocol can demonstrate stent graft
migration and structural disintegration. DUS is able to
determine aneurysm size, identify and characterize endo-
leaks, and visualize ﬂow that may indicate adverse structural
issues such as limb kinking. However, its sensitivity in the
detection of endoleaks varies between 42.9%11 and 97%,12
with speciﬁcity ranging from 75% to 98.4%.12-16 A more
recent modiﬁcation is contrast-enhanced ultrasound
(CEUS). Several studies have shown CEUS to have compa-
rable, if not superior, accuracy tomultiphasic CTA in detect-
ing endoleaks, while avoiding CTA associated complications
and costs.17 It remains unclear, however, what the applica-
tion of CEUS should be in EVAR surveillance.
This study considered CEUS as an adjunct surveillance
modality in selected cases where DUS and/or single arterial
phase CTA were nondiagnostic, contraindicated, failed to
conﬁdently identify the presence of an endoleak when there
was associated signiﬁcant aneurysm expansion ($5 mm), or
ascribe an endoleak type. The aim was to identify a role for
CEUS within the EVAR surveillance program.
METHODS
In our institution the surveillance protocol following
EVAR is based on 1 month single arterial phase CTA,
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CTA is reserved for cases when AXR and DUS identify
abnormal results or provide incomplete diagnosis. These
include features of stent graft migration, DUS ﬁnding of
a stent graft related endoleak, endoleak that cannot be con-
ﬁdently characterized, aneurysm enlargement, and stenosis
or kinking of iliac limbs. CEUS became available at our
institution in April 2010, and this study documents its
introduction into the EVAR surveillance program. All cases
where standard surveillance identiﬁed an issue were dis-
cussed at a multidisciplinary meeting, and a decision on
how to proceed was made on a case by case basis.
Indications for CEUS. Between April 2010 and July
2011 patients in whom there were discordant or nondiag-
nostic ﬁndings between imaging modalities underwent
CEUS. All patients requiring CEUS were prospectively
evaluated and followed up over the study period.
Indications which prompted CEUS were as follows.
(1) Endoleak classiﬁcation (group 1): In this group of
patients, CEUS was utilized to characterize an
endoleak type that other imaging modalities had
failed to clarify.
(2) Signiﬁcant aneurysm expansion ($5 mm) with-
out identiﬁable endoleak (group 2).
(3) Target vessel patency after fenestrated endovascu-
lar repair in patients with CKD 4 and in whom
DUS was nondiagnostic (group 3).
CEUS technique. CEUS was performed by vascular
sonographers trained in post-EVAR imaging. A Philips
iU22 ultrasound scanner (Philips Healthcare, DA Best, The
Netherlands) was used with an abdominal curved array
probe (2-5 MHz). The contrast used was a second gener-
ation agent (SonoVue; Bracco, Milan, Italy) made of
sulphur hexaﬂuoride-ﬁlled microbubbles with ﬂexible lipid
shells, which is eliminated through the respiratory system.
Its use is contraindicated in certain patient populations
including those with unstable angina or a recent episode of
acute coronary syndrome, as such all patients were screened
with regard to the contraindications prior to introduction of
the contrast agent. Low mechanical index (0.12) was used
to avoid early destruction of the microbubbles. Contrast
techniques apply a low acoustic pressure to produce images
based on nonlinear acoustic interaction between the ultra-
sound systems and the microbubbles. The microbubbles
oscillate and resound allowing continuous display of con-
trast enhancement on grayscale images.18
Axial and longitudinal images were used for the ultra-
sound imaging. The area of suspicion was identiﬁed using
grayscale images, then an initial contrast agent bolus of
1 mL was administered through an 18-20 gauge cannula
placed in the antecubital fossa followed by 5 mL normal
saline ﬂush. The contrast image was viewed on a split image
screen with the grayscale image adjacent. This initial dose
of contrast was used to identify and localize the endoleak
to a region of the aneurysm. Where an endoleak was found,
a more focused examination of that region was conductedwith a further 1 mL bolus of contrast agent. This was used
to compare the timing of contrast enhancement within the
endograft and the aneurysm. Immediate endoleak en-
hancement would suggest a graft related type I or III endo-
leak whereas a delay of greater than 5 seconds would
suggest a type II endoleak. Indeed, in all patients in this
study in whom a type I endoleak was observed, contrast
enhancement was seen arriving in the aneurysm and stent
graft simultaneously. A further bolus was given to interro-
gate other areas of concern when necessary (Fig 1).
Findings of all three imaging modalities were reviewed
and discussed at a multidisciplinary team meeting, com-
prising vascular radiologists, vascular and endovascular sur-
geons, and specialist vascular sonographers to achieve
a diagnosis and formulate an appropriate management plan.
RESULTS
During the study period, 539 patients underwent
surveillance following the local EVAR surveillance pro-
tocol. Thirty-three patients (median age, 79 years; range,
66-90; 28 male) progressed to have CEUS (6%). No
patient suffered any complication or adverse event related
to the contrast used. Median follow-up after EVAR was
23 months (range, 0-132 months), and the median aneu-
rysm diameter was 6.9 cm (range, 5.2-9.3 cm) at the
time of last follow-up. All patients had undergone elective
endovascular repair. The bifurcated endografts implanted
comprised ﬁve Excluder (Gore, Flagstaff, Ariz), 19 Zenith
(Cook, Bloomington, Ind), seven of which were fenes-
trated endografts, eight Endurant (Medtronic, Minneapo-
lis, Minn), and one Talent (Medtronic). CEUS was
performed using a median contrast volume of 2 mL (range,
1-4 mL). A summary of all the patients’ results are dis-
played in the Table. Of the 506 patients who did not
have CEUS as part of their surveillance, further informa-
tion was available on 470 patients. Of these, 332 patients
(70.6%) followed a standard surveillance protocol as out-
lined earlier. The remaining patients had surveillance with
CTA in addition to the standard protocol for a number
of reasons: including DUS being considered nondiagnostic
because of obesity, patients enrolled in the EVAR trials and
therefore had CT follow-up, and patients for whom extra
surveillance with CTA was deemed necessary because of
ﬁndings during the standard follow-up. A total of 137
patients (41.2%) in the standard surveillance group were
found to have an endoleak at some point during their
follow-up. The vast majority of these were found to be
type II endoleaks (127 patients; 38.2%), with 10 patients
(3%) found to have a type I endoleak.
Group 1. This group consisted of 27 patients in whom
an endoleak had been noted on at least one imaging
modality that required further characterization. Within
this group, CEUS conﬁdently deﬁned four type I endoleaks
(Fig 2) requiring secondary intervention; these were all
conﬁrmed to be type I endoleaks at the secondary inter-
vention. One patient underwent laparotomy and suturing of
the stent graft, and the other three had successful endo-
vascular procedures to abolish the type I endoleak.
Fig 1. Type II endoleak arising from the inferior mesenteric artery (IMA). The image on the left shows the two limbs
of the stent graft (blue arrows) at the level of the IMA 26 seconds after the beginning of the scan. Contrast is seen to
begin ﬁlling the limbs of the stent graft. After another 9 seconds, contrast is ﬁrst seen in the IMA in the middle image
(yellow curved arrow). The image on the right shows contrast within IMA moving into the aneurysm after another 8
seconds. The time delay conﬁrms a type II endoleak.
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inally suspected to be type I or III graft-related endoleak)
were identiﬁed; ﬁve of these patients went on to require
secondary intervention and all were conﬁrmed as type II
endoleaks at either DSA or operation. All ﬁve patients had
an attempt at coil embolization of the feeding artery respon-
sible for the endoleak. This was successful in four patients
with one patient requiring laparotomy and under-running
of the median sacral artery to abolish the endoleak.
In the remaining two patients an endoleak was
excluded at CEUS, however, in one of these patients,
a type II endoleak was found on further surveillance
DUS. All patients, irrespective of whether they underwent
secondary intervention, were returned to surveillance.
Group 2. This group consisted of four patients (Table;
28-31) in whom there was no evidence of endoleak on
both DUS and CTA in spite of signiﬁcant aneurysm
expansion. CEUS concurred in three patients. Subsequent
delayed phase CTA concurred with the CEUS ﬁnding in
two patients but in one it identiﬁed a small type II endo-
leak, although treatment was not deemed necessary. In the
fourth patient, a type II endoleak was demonstrated on
CEUS and at DSA during which a successful coil emboli-
zation undertaken.
Group 3. This group comprised two patients with
fenestrated endografts and bilateral renal stents (Table;
32 and 33). Surveillance DUS did not adequately
demonstrate renal perfusion and pre-existing CKD 4
precluded routine CTA. Satisfactory perfusion was con-
ﬁrmed, however, on CEUS allowing both patients to re-
turn to standard surveillance.
DISCUSSION
This prospective study suggests that there is a beneﬁt in
using CEUS as an adjunct to DUS and CTA in EVARsurveillance. Biphasic CTA is considered the gold standard
but does not indicate direction of blood ﬂow or provide
accurate temporal information and may not be able to clas-
sify some endoleaks.19 With regard to direction of ﬂow,
DUS is considered superior to multiphasic CTA by some
authors,9 and this may be further enhanced through the
introduction of microbubbles. Furthermore, CTA requires
the administration of iodinated contrast media, of which
a greater volume is given during multiphasic studies, which
may have a nephrotoxic effect. It is for this reason we have
preferred the use of single phase CTA at our institution.
There have been no reported instances of nephrotoxicity
related to the use of ultrasound contrast media highlighting
a beneﬁt of CEUS over CTA in these difﬁcult cases. The
additional advantage of reduced radiation exposure and
cost further strengthens the argument for CEUS as an
adjunct to a surveillance program. The need for CTA still
remains when planning an intervention strategy and in
particularly complex or ambiguous cases, multiphasic
CTA still has a diagnostic role. Several studies have demon-
strated 100% sensitivity of CEUS in comparison to single
and biphasic CTA in the detection of endoleak.3,20
Another larger study by Iezzi et al21 demonstrated 82%
speciﬁcity and 98% sensitivity of CEUS and has advocated
the sole use of CEUS for surveillance if the initial postop-
erative CTA was uncomplicated. However, the purpose
of surveillance is to evaluate and address complications
that may render the procedure a failure. Although type I
and III endoleaks represent a signiﬁcant complication
necessitating treatment, the majority of type II endoleaks
are low risk and can be managed conservatively.22 As
such, the ubiquitous use of a highly sensitive imaging
modality such as CEUS may result in an increase in the
identiﬁcation of “harmless” endoleaks, prompting unnec-
essary conﬁrmatory imaging with CTA. A surveillance
Table. Classiﬁcation of endoleaks by DUS and/or CTA vs CEUS results and clinical outcomes
Patient
Aneurysm
expansion DUS CTA
Clinical
question
CEUS
(months after
EVAR) CEUS Clinical outcome
1 þ14 mm NAa II Endoleak type 60 II (LA>IMA) (II seen at DSA) LA
embolization
Onyx Aneurysm Embolization
2 þ10 mm II NA Endoleak type 70 II (IMA->LA) (II seen at DSA) IMA
embolization
3 þ10 mm II II
Effacement
Endoleak type
Rule out (I)
26 I (I seen at operation) open
conversion
4 þ7 mm II II
Effacement
Endoleak type
Rule out (I)
48 II (IMA->LA) (II seen at DSA and
operation) open conversion
5 þ7 mm II NA Endoleak type 23 II (IMA) Surveillance
6 þ6 mm II/III II/III Endoleak type 24 II (IMA) Surveillance
7 þ6 mm II II Endoleak type 37 II (IMA, LA) (II seen at DSA) LA
embolization
8 þ6 mm II NA Endoleak type 52 II (IMA->LA) Surveillance
9 þ6 mm II II Endoleak type 5 II (IMA->LA)
I suspected
(II seen at DSA) IMA
embolization
10 þ5 mm I/II I/II Endoleak type 26 I (I seen at DSA) limb extension
and IIA embolization
11 þ5 mm II II Endoleak type 12 II (LA) Surveillance
12 þ5 mm II/I NA Endoleak type 32 II (IMA-LA) Surveillance
13 0 No endoleak I Endoleak type 1 II (IMA->LA) Surveillance
14 0 No endoleak II/I Rule out (I) 1 II (IMA) Surveillance
15 0 No endoleak II (2) Endoleak type 3 II (IMA, LA) Surveillance
16 0 I Known fabric tear Endoleak type 51 II (IMA) Surveillance
17 0 III II/III Endoleak type 2 II (LA) Surveillance
18 0 II II/III Endoleak type 12 II (LA->IMA) Surveillance
19 0 II II/III Endoleak type 12 II (LA) Surveillance
20 0 No endoleak II Endoleak type 2 No endoleak Repeat DUS->II. Surveillance
21 0 Pulsatile
thrombus
in sac
NA Endoleak type 132 No endoleak Surveillance
22 0 II II Rule out (I) 96 II (LA->IMA) Surveillance
23 0 II I/II Endoleak type 6 II (LA->IMA) Surveillance
24 0 I/II II Rule out (I) 1 II (IMA-LA) Surveillance
25 0 I No endoleak Rule out (I) 7 II Surveillance
26 0 NAa I/II
Migration
Endoleak type 13 I and II (I and II seen at DSA) cuff
extension
27 0 ND I (renal stent) Rule out (I) 0 I (related to
renal stent)
(I seen at DSA) renal stent
angioplasty þ overlapping
stent
28 þ10 mm No endoleak No endoleak Presence of
endoleak
60 No endoleak Delayed phase CT: II
29 þ8 mm No endoleak Effacement Presence of
endoleak
Rule out (I)
48 No endoleak Delayed phase CT: no
endoleak
30 þ7 mm No endoleak No endoleak
Effacement
Presence of
endoleak
Rule out (I)
44 No endoleak Delayed phase CT: no
endoleak
31 þ6 mm No endoleak
SMA
occlusion
No endoleak Presence of
endoleak
SMA
patency
62 II, SMA
stenosis
(II seen at DSA) LA
embolization
32 0 Renal
arteries
not seen
Contraindicated Target vessel
patency
4 Kidney well
perfused
Surveillance
33 0 Renal
perfusion
Not
detected
Contraindicated Renal artery
patency
0 Kidneys well
perfused
Conservative
CEUS, Contrast-enhanced ultrasound; CTA, computed tomography angiography; DSA, digital subtraction angiography; DUS, duplex ultrasound; EVAR,
endovascular aneurysm repair; FEVAR, fenestrated endovascular aneurysm repair; IMA, inferior mesenteric artery; LA, lumbar artery (-> speciﬁes ﬂow
direction); NA, not available; ND, nondiagnostic; I, type I endoleak; II, type II endoleak; III, type III endoleak.
aIn these two patients, DUS was found previously to be nondiagnostic due to obesity and was not therefore performed prior to CEUS.
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Fig 2. Proximal (longitudinal view) type I endoleak (yellow arrow)
that becomes apparent at the same time as the enhancement within
the graft (blue arrow).
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patients in whom there has been signiﬁcant aneurysm
expansion or migration and, in such cases, if the identiﬁca-
tion of an endoleak remains elusive then CEUS may eluci-
date the situation and obviate the need for further
intervention. If doubt remains after CEUS then delayed
phase CTA may contribute.23 In our study, delayed phase
CTA was utilized to investigate three patients who had an
aneurysm expansion without evidence of an endoleak on
CEUS, one of whom had an endoleak that did not require
treatment. This demonstrates the need for multiple
imaging modalities in understanding complex situations,
and no one modality represents the panacea. Although
evidence is available on the use of CEUS in post-EVAR
surveillance, its role remains undeﬁned. We utilized
CEUS in this study to clarify clinical dilemmas, and it
proved effective in classifying undetermined endoleaks
through temporal hemodynamic information, albeit in
a relatively small number of patients. The successful conﬁr-
mation of type II endoleaks, the exclusion of type I and III
endoleaks, and the conﬁrmation of renal perfusion targeted
subsequent imaging and secondary interventions.
DUS limitations, with regard to its unsatisfactory sensi-
tivity and speciﬁcity in endoleak detection, are mainly due
to the burden of the echo reﬂection by the metallic compo-
nent of the graft, extended calciﬁcations, obesity, low ﬂow
endoleaks, and operator experience.24 Although CEUS can
facilitate imaging, it has its own limitations. Obesity andbowel gas can interfere with ultrasound scanning, and
patient collaboration is always required.3 The examination
is operator dependent and requires speciﬁc skills and
adequate specialized training. The administration of con-
trast through intravenous access and the more detailed
scanning techniques dictate a longer procedure with a
higher cost. The cost of contrast medium per scan is
V61.50. Although it is difﬁcult to quantify actual costs
for the various imaging modalities used in our surveillance
program, the estimated costs from the departments in our
institution is as follows: V110.70 for standard DUS,
V172.20 for CEUS, and V209.10 for CTA. (All prices
converted from British pounds to Euros, £1 ¼ V1.23.)
The limitations of this study include its retrospective
nature and relatively small numbers of patients who under-
went CEUS; however, the main weakness of this study is
that it was not a case-control study. As such, it is impos-
sible to deﬁne the sensitivity or speciﬁcity of CEUS from
our results and inform its accuracy as a standalone method
of surveillance. However, the aim of our study was
primarily to deﬁne a role for CEUS and as we believed it
was an adjunct to our program rather than a new gold
standard, it was outside the remit to compare its perfor-
mance with a control group. This does, however, raise an
interesting question as to the future of CEUS. Further
study such as a randomized controlled trial would be
necessary to understand the utility of CEUS more clearly;
however, it is noted that the design of any such trial would
be challenging.
CONCLUSIONS
A potential role for CEUS is facilitating the resolution
of clinical uncertainties that arise from conventional
imaging modalities, particularly in identifying and charac-
terizing endoleaks. It remains limited, however, by an
inability to provide information on graft anchoring, integ-
rity, and aneurysm morphology.24 In this study, CEUS
proved to be useful in investigating 6% of patients enrolled
into the EVAR surveillance program and has become an
important adjunct in the armamentarium of imaging
modalities for the follow-up of these patients.
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